Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Heart Failure Drug Shows Promise in Phase III Clinical Trial

Published: Monday, November 12, 2012
Last Updated: Sunday, November 11, 2012
Bookmark and Share
Results were presented by John Teerlink at the American Heart Association’s Scientific Sessions 2012.

Hospitalized heart failure patients who received the drug, serelaxin, in a phase III clinical trial had fewer disease symptoms and as a group experienced 37 percent fewer deaths over six months.

The results were presented Tuesday at the American Heart Association’s Scientific Sessions 2012 in Los Angeles by John Teerlink, MD, co-principal investigator of the study.

“Current therapy for acute heart failure has remained unchanged for decades,” said Teerlink, a UCSF professor of medicine and director of the heart failure program at the San Francisco Veterans Affairs Medical Center.

Teerlink continued, “Our findings suggest serelaxin holds promise as the first evidence-based therapy for acute heart failure to substantially improve patients’ symptoms and clinical outcomes, including death.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agricultural Intervention Improves HIV Outcomes
A multifaceted farming intervention can reduce food insecurity while improving HIV outcomes in patients in Kenya, according to a randomized, controlled trial led by researchers at UC San Francisco.
Thursday, August 20, 2015
Type 1 Diabetes Drug Proves Effective in Clinical Trial
Drug developed by UCSF researcher shows promise for blocking advance of disease in earliest stages.
Thursday, August 08, 2013
HIV Testing Increased and Infection Reduced in Africa with Community Intervention
Free mobile HIV testing and counseling, same-day results and post-test support reduces HIV infections by 14 percent.
Thursday, March 07, 2013
Researchers Identify Protein Key in Proliferation of Lymphoma Cells
Inhibiting PERK protein could reduce formation of cancerous tumors.
Thursday, November 29, 2012
Scientific News
Therapy Halts Progression of Lou Gehrig’s Disease
Researchers at Oregon State University announced today that they have essentially stopped the progression of amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, for nearly two years in one type of mouse model used to study the disease – allowing the mice to approach their normal lifespan.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
UTSW Researchers Identifies How Drugs Alter Pancreatic Cancer Cells
The findings were published in Cell Reports.
Researchers Identify Process that Causes Chronic Neonatal Lung Disease
Study determines how the NLRP3 inflammasome activates the protein Interleukin 1 beta.
Dengue Vaccine Enters Phase 3 Trial
Investigational vaccine to prevent ‘breakbone fever’ developed at NIH.
Trying to Conceive Soon After a Pregnancy Loss May Increase Chances of Live Birth
NIH study finds no reason for delaying pregnancy attempts after a loss without complications.
BRCA1 Deficiency Increases the Sensitivity of Ovarian Cancer Cells to Auranofin
An anti-rheumatic drug could improve the prognosis for ovarian cancer patients exhibiting a deficiency of the DNA repair protein BRCA1, a study suggests.
Shingles Vaccine Helps Protect Older Patients with End-stage Renal Disease
Kaiser Permanente study advances knowledge about safety and effectiveness of vaccine commonly given to older adults.
AMRI Acquires Whitehouse Laboratories
Strategically extends AMRI's analytical offerings in rapidly expanding area of outsourcing services.
Scroll Up
Scroll Down
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!